scholarly journals THE INVESTIGATION OF DNA DAMAGE IN LYMPHOCYTES BY COMET ASSAY IN CHRONIC VIRAL HEPATITIS B PATIENTS

2017 ◽  
Vol 22 (2) ◽  
pp. 64-68
Author(s):  
A. O Mikhailov ◽  
A. F Popov ◽  
N. S Ivanova ◽  
A. I Simakova
Keyword(s):  
Dna Damage ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Comet Assay ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
The Body ◽  
Control Group ◽  
Blood Samples ◽  
Viral Hepatitis B

The investigation of the degree of the lymphocyte DNA damage in chronic viral hepatitis B (HBV) patients is of interest for several reasons. Firstly, it is possible to judge indirectly about the depth of the pathological process at the level of the whole organism, with bearing in mind features of the pathogenic replication of hepatitis B virus. Secondly, it is possible to give an estimation of the degree of genotoxic impact of the virus on blood cells that plays an essential role in the shaping of the immune response of the body. The study was executed on 50 blood samples from HBV patients, divided in 5 groups on the fibrosis grade according to METAVIR score: F0 (n = 10), F1 (N = 10), F2 (N = 10), F3 (n = 10), F4 (n = 10). The control group was consisted of 43 volunteers matched by the age and gender without concomitant diseases. From blood samples taken at the time of the admission to the hospital lymphocytes were isolated by density gradient on Ficoll-urografin. The degree of DNA damage in lymphocytes was determined by virtue of alkaline version of the DNA comet assay. There was noted the direct relationship between an increase in % DNA in the tail of comets and the grade of liver fibrosis. So in the control group, % DNA in the tail accounted for 3.75 ± 1.44. In the F0 group % of DNA in the tail was 5.07 ± 1.25, F1 - 6.79 ± 1.79, F2 - 7.65 ± 1.62, F3 - 8.05 ± 1.18, F4 - 9.84 ± 3.09. It is noteworthy that in groups F2, F3, F4 differences were statistically significant in comparison with the control group. Also there was noted the presence of apoptotic cells in F3, F4 groups: 1 and 0.88%, respectively. Identified changes are both important in the description of to molecular patterns of the pathogenesis of chronic hepatitis B associated with damage, and also can serve as an indirect indication of the stage of liver fibrosis.

scholarly journals PROSPECTS OF THE USE "STIMFORTE" IN CHRONIC HEPATITIS B

2013 ◽  
Vol 18 (5) ◽  
pp. 15-20
Author(s):  
L. V Pogorelskaya ◽  
I. N Khlopova ◽  
S. S Grigoryan ◽  
I. P Tryakina ◽  
N. A Rick ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Hepatitis B ◽  
Well Being ◽  
Chronic Viral Hepatitis ◽  
Control Group ◽  
Positive Hbsag ◽  
Viral Hepatitis B

Despite the fact that over the last few years downward trend in the incidence of acute forms of viral hepatitis B continues, the incidence of chronic hepatitis B (CHV) has increased by 2.5 times since 1998. To date, there are a sufficient number of antiviral drugs, but their use is associated with a set of contraindications, as well as the development of resistance. In this study there was performed an evaluation of a new national drug " Stimforte " in patients with chronic viral hepatitis B (CVHB - DNA positive, HBsAg - positive) at the stage of exacerbation. In the study there were included 28 patients with chronic hepatitis B (HBsAg positive), at different grades of activity, at a stage of viral replication. The diagnosis of chronic hepatitis B was made on the presence in a history acute viral hepatitis for more than 1 year, complaints, hepatolienal, astenovegetative, cytolytic syndromes, the presence of DNA-HBV, anti-HBcore IgM, HBsAg. After 1 course of treatment with " Stimforte " the well-being of patients has improved: in 30% of patients asthenic- vegetative syndrome had disappeared, weakness, fatigue and dyspeptic symptoms were decreased. The use of "Stimforte" in chronic hepatitis B with positive HBsAg at the stage of exacerbation contributed to a more rapid normalization of such indices as ALT, AST, compared with those in the control group. Long-term biochemical and virological remission was achieved in 40 %. It is established that during the treatment the viral load was reduced progressively until the undetectable or low level of HBV DNA and anti-HBc IgM disappeared. In only one case an allergic reaction was observed, which has not hindered to perform a complete course of treatment. No other side effects were detected. The inclusion of the drug "Stimforte" in the complex therapy of patients with exacerbation of chronic hepatitis B reduces the time of recovery of immune status and functional activity of IFN system and contributes to reduction of the viral load or elimination of the virus.

scholarly journals Dna damage in lymphocytes in chronic viral hepatitis B, C

2017 ◽  
Vol 9 (2) ◽  
pp. 29-36
Author(s):  
A. O. Mikhailov ◽  
A. F. Popov ◽  
N. S. Ivanova ◽  
A. I. Simakova
Keyword(s):  
Dna Damage ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Viral Hepatitis B

scholarly journals CHRONIC VIRAL HEPATITIS B;

2018 ◽  
Vol 25 (08) ◽  
pp. 1218-1222
Author(s):  
Nasreen - ◽  
Aqeel Ahmed Channa ◽  
Abdul Raheem Memon ◽  
Syed Zulfiquar Ali Shah ◽  
Muhammad Iqbal
Keyword(s):  
Liver Fibrosis ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
University Hospital ◽  
Female Population ◽  
Male And Female ◽  
Non Invasive ◽  
Viral Hepatitis B ◽  
The Mean

Objectives: To determine the frequency of liver fibrosis by non invasive markerin patients with chronic viral hepatitis B. Study Design: Cross sectional clearly investigate aboutchronic viral hepatitis population. Setting: Liaquat University Hospital Hyderabad. Period: Sixmonths, 09-Jan-2014 to 08-July-2014. Patients and Methods: All the patients of 16-50 years ofage, of either gender with chronic viral hepatitis B infection for more than 6 months duration wereadmitted and evaluated for liver fibrosis through non invasive marker (APRI). The SPSS was usedto manipulate the data. Results: During six month study period, total 140 patients with chronicviral hepatitis B infected patients were evaluated for liver fibrosis. Majority of patients were fromurban areas 112/140 (80%). The mean ±SD for age of patients with chronic viral hepatitis Binfection was 37.95±9.77. The mean age ±SD of hepatic fibrotic patients was 35.72±7.62.The mean ±SD for age of male and female population was 35.83±8.74 and 33.83 ± 6.53respectively. The mean ± SD for APRI score in hepatic fibrotic subjects was 1.31±0.31 while inrelation to liver fibrotic male and female patients it was 0.91±0.21 and 1.00±0.32 respectively.Majority of the subjects were 30-39 years of age and the male population predominant (p=0.02)whereas the liver fibrosis was identified in 89/140 (63.5) [p=<0.01] as far as gender distributionis concerned. Conclusion: APRI may be used as a simple and readily available tool for thediagnosis of significant fibrosis in patients with chronic viral hepatitis B.

Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients

2015 ◽  
Vol 47 (7) ◽  
pp. 1209-1217 ◽  
Author(s):  
Olga Hilda Orăşan ◽  
Mădălina Sava ◽  
Mihaela Iancu ◽  
Angela Cozma ◽  
Aniela Saplonţai-Pop ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Hemodialysis Patients ◽  
Chronic Viral Hepatitis ◽  
Chronic Hemodialysis ◽  
Viral Hepatitis B

scholarly journals Features during labor in women with chronic hepatitis B

2015 ◽  
Vol 96 (1) ◽  
pp. 10-12
Author(s):  
N D Shoonaeva
Keyword(s):  
Hepatitis B ◽  
Cesarean Section ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Control Group ◽  
Study Group ◽  
Fetal Hypoxia ◽  
Premature Rupture Of Membranes ◽  
Early Postpartum ◽  
Viral Hepatitis B

Aim. To examine the course of labor in women with chronic hepatitis B.Methods. The course of labor was studied in 391 female patients with chronic viral hepatitis B, included in the study group (mean age 22.7±2.5 years), who delivered off in the National Maternity Hospital (Bishkek). The control group included 59 healthy women in labor (mean age 22.5±1.3 years).Results. The vast majority of patients - 53 (89.8%) of the control group and 328 (83.9%) of the study group - had delivered off at term. Post-term births were registered in both groups. Operative delivery by cesarean section was performed in 13.0% of chronic viral hepatitis B cases - by 4.5% higher compared to control group. In the study group, planned cesarean section was performed in 21 (5.4%) patients, the main indication was burdened obstetric history - in 8 (2.0%) patients; 5 (1.3%) patients had multiple indications. Emergency operations were conducted in 30 (7.7%) patients. Indications were premature rupture of membranes - 15 (3.8%) of cases, fetal hypoxia during labor and multiple indications - 10 (2.6%) cases each. The average blood loss at cesarean section in the group of patients with chronic viral hepatitis B was 870±15.2 ml, compared to 700±10.2 ml in the control group, which can be associated with low coagulation seen in hepatitis. Comparative analysis of the complications rate in the control group revealed that delayed rupture of membranes was the most frequent - 11 (18.6%) cases, followed by intrauterine fetal hypoxia - 5 (8.5%) cases, early postpartum bleeding - 4 (6.8%) cases, hypertensive disorders at labor and retained placenta - 3 (5.1%) cases each. In the group with chronic viral hepatitis B, premature rupture of membranes occurred in 51.5% of cases, (relative risk 2.8). Early postpartum bleedings were seen in 38.9% of the cases at the main group (relative risk 5.7).Conclusion. The above data gives us every reason to include women with chronic viral hepatitis B at high-risk group for possible bad pregnancy and childbirth outcomes both for the mother and the fetus.

scholarly journals THE EFFECT OF CHRONIC VIRAL HEPATITIS B AND C ON BONE MINERAL DENSITY

2015 ◽  
Vol 18 (4) ◽  
pp. 138-142
Author(s):  
Ecaterina-Constanta Barbu ◽  
◽  
Cristina-Emilia Chitu-Tisu ◽  
Mihai Lazar ◽  
Ramona Stefania Popescu ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Bone Mineral ◽  
Chronic Viral Hepatitis ◽  
Mineral Density ◽  
Total Hip ◽  
Viral Hepatitis B ◽  
Low Bmi

Objectives. Chronic viral hepatitis B and C represent an important health burden all over the world. Reduced bone mineral density is an extrahepatic complication which has been found in patients with chronic liver disease. The aim of our study was to identify bone mineral impairment (osteopenia/osteoporosis) and the risk factors that are correlated with its severity, in patients with chronic viral hepatitis B (CHB) and C (CHC). Material and methods. Anthropometric, biological parameters and bone mineral density (BMD) were measured in 60 patients with CHB (n = 30) and CHC (n = 30). BMD was assessed using Dual Energy X-ray Absorptiometry (DEXA) in the hip and lumbar spine regions, inclusively a whole scan (total body). Results. Sixty patients (mean age 44.93 years, range: 20-70) were enrolled, including 30 CHB patients (mean age 46.43 years, range: 20-70) and 30 CHC patients (mean age 43.43 years, range: 28-64). Forty of patients were men (66.66 %). Active smokers were 16 patients (26.66 %). Meanbody mass index (BMI) was 25.38 kg/m2 (range: 16.70-38.40). At baseline, 21 of 60 (35%) of the patients had evidence of osteopenia and 4 of 60 (6.66%) of patients, respectively presented osteoporosis at LS. At total hip, 22 of 60 of the patients (36.66%) recorded osteopenia; osteoporosis was found at 7 patients (11.66%) at total hip assessment. Low BMD values at different regions correlated significantly with low BMI, smoking and liver fibrosis grade. Conclusions. Our results suggest that bone mineral metabolism disorders exist in patients with chronic viral hepatitis B and C who are active smokers, presenting low BMI and advanced liver fibrosis, even without liver cirrhosis.

scholarly journals Non-invasive assessment of liver fibrosis through FibroMeter in patients with chronic viral hepatitis B and C

2014 ◽  
Vol 14 (S7) ◽  
Author(s):  
Oana Săndulescu ◽  
Anca Streinu-Cercel ◽  
Gabriela Ceapraga ◽  
Mara Constantinescu ◽  
Adrian Streinu-Cercel
Keyword(s):  
Liver Fibrosis ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Non Invasive ◽  
Viral Hepatitis B

scholarly journals Diagnostic Usefulness of Real-Time Elastography for Liver Fibrosis in Chronic Viral Hepatitis B and C

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Young Woon Kim ◽  
Jung Hyun Kwon ◽  
Jeong Won Jang ◽  
Min Ju Kim ◽  
Byong Sun Oh ◽  
...  
Keyword(s):  
Liver Fibrosis ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Real Time ◽  
Chronic Viral Hepatitis ◽  
Advanced Fibrosis ◽  
Discrimination Power ◽  
Viral Hepatitis B ◽  
Diagnostic Usefulness ◽  
Liver Fibrosis Index

The aim of this study was to investigate the diagnostic usefulness of real-time elastography (RTE) for liver fibrosis in chronic viral hepatitis B (CHB) and C (CHC). Fifty-one and thirty-two of the patients were diagnosed with CHB and CHC, respectively. Enrolled patients underwent liver biopsy and RTE. The FIB-4 index and aspartate transaminase-to-platelet ratio index (APRI) were also measured. The liver fibrosis index (LFI) by RTE increased significantly with the Knodell fibrosis stage:3.14±0.62for F0,3.28 ± 0.42for F1,3.43 ± 0.53for F3, and4.09 ± 1.03for F4 (P=0.000). LFI as well as APRI, FIB-4, platelet, albumin, and prothrombin time showed the difference in patients with advanced fibrosis (≥F3) and those with mild fibrosis (≤F1). In addition, RTE had better discrimination power between≥F3 and F4 than between FIB-4 and APRI. In CHC patients, the area under receiver operating characteristic curves of RTE for advanced fibrosis was higher than that in CHB patients (0.795 versus 0.641). RTE is useful for the assessment of advanced fibrosis in patients with CHB and CHC and has better discrimination power than other serologic markers.

Sign in / Sign up

Export Citation Format

Share Document